Abstract:Mangrove and its derived actinobacteria strains are well known for producing novel secondary metabolites and possessing highly effective bioactive compounds, possibly due to biochemical adaptation to the special intertidal ecosystem (Li et al., 2013Li X.G. Tang X.M. Xiao J. et al.Harnessing the potential of halogenated natural product biosynthesis by mangrove-derived actinomycetes.Mar Drugs. 2013; 11: 3875-3890Crossref Scopus (13) Google Scholar). Streptomyces xiamenensis was identified as a novel species of actinobacteria from mangrove sediments (Xu et al., 2009Xu J. Wang Y. Xie S.J. et al.Streptomyces xiamenensis sp. nov., isolated from mangrove sediment.Int J Syst Evol Microbiol. 2009; 59: 472-476Crossref Scopus (44) Google Scholar). In this study, a series of benzopyran derivatives, named xiamenmycin A-D (1-3), were discovered from S. xiamenensis as potential lead compounds against excessive fibrotic diseases (Figure 1) (Xu et al., 2012Xu M.J. Liu X.J. Zhao Y.L. et al.Identification and characterization of an anti-fibrotic benzopyran compound isolated from mangrove-derived Streptomyces xiamenensis.Mar Drugs. 2012; 10: 639-654Crossref PubMed Scopus (29) Google Scholar; You et al., 2013You Z.Y. Wang Y.H. Zhang Z.G. et al.Identification of two novel anti-fibrotic benzopyran compounds produced by engineered strains derived from Streptomyces xiamenensis M1-94P that originated from deep-sea sediments.Mar Drugs. 2013; 11: 4035-4049Crossref Scopus (14) Google Scholar). The promising anti-fibrotic activities of xiamenmycins have triggered efforts to determine the structure, increase structural diversity, and find the gene cluster responsible for biosynthesis. Structurally, the absolute configuration of xiamenmycin A was determined by extensive spectroscopic data analyses, Mosher’s method, Marfey’s reagent, and quantum mechanical calculations (Xu et al., 2012Xu M.J. Liu X.J. Zhao Y.L. et al.Identification and characterization of an anti-fibrotic benzopyran compound isolated from mangrove-derived Streptomyces xiamenensis.Mar Drugs. 2012; 10: 639-654Crossref PubMed Scopus (29) Google Scholar). Genetically, the introduction of spontaneous rifampicin resistance combined with streptomycin resistance by introducing a mutated rpsL gene into S. xiamenensis was performed to increase the production of its secondary metabolites and two more new benzopyran derivatives were isolated (You et al., 2013You Z.Y. Wang Y.H. Zhang Z.G. et al.Identification of two novel anti-fibrotic benzopyran compounds produced by engineered strains derived from Streptomyces xiamenensis M1-94P that originated from deep-sea sediments.Mar Drugs. 2013; 11: 4035-4049Crossref Scopus (14) Google Scholar). The biosynthetic pathway was elucidated and all the genes in the pathway were genetically and biochemically characterized. Pharmacologically, we found that xiamenmycin A could significantly inhibit cell proliferation and activation of primary human dermal fibroblast (HDF), and reduced the contractile ability of HDF, indicating that the compound might have anti-fibrotic effect (Liu et al., 2013Liu X.J. Xu M.J. Fan S.T. et al.Xiamenmycin attenuates hypertrophic scars by suppressing local inflammation and the effects of mechanical stress.J Invest Dermatol. 2013; 133: 1351-1360Abstract Full Text Full Text PDF PubMed Scopus (41) Google Scholar). By using a mechanical stretch-induced mouse hypertrophic scar model, we found that xiamenmycin A significantly attenuated hypertrophic scar formation and had no significant toxic effect on mice. Furthermore, the compound could suppress local inflammation by reducing CD4+ lymphocyte and monocyte/macrophage retention in fibrotic foci and blocked fibroblast adhesion with monocytes. Both in vivo and in vitro studies found that the compound inhibited the mechanical stress-induced profibrotic effects by suppressing proliferation, activation, and fibroblast contraction, and inactivating FAK, p38, and Rho guanosine triphosphatase signaling. From the primary analysis of the structure–activity relationship (SAR) between xiamenmycins, we found that compounds 1–3 shared the same benzopyran skeleton and isoprene side chain. The only difference in the structures is in the amino-acid moiety (on position 1′). Xiamenmycin C (2) was found to exhibit inhibitory effects on the cell proliferation of human lung fibroblasts (WI26) using lower doses compared with xiamenmycin. It seems that the benzopyran skeleton is crucial for the anti-fibrotic activity. Xiamenmycin D (3) showed anti-fibrotic activity similar to xiamenmycin. It indicated that the methylation at C6′ position may not effect the bioactivity. As a type of potential anti-fibrotic drug, more diverse benzopyran structures are needed for the investigation of the SAR. Taken together, our data suggest that xiamenmycin A could simultaneously suppress both the inflammatory and mechanical stress responses, which are the two pivotal pathological processes in hypertrophic scar formation, thus suggesting that xiamenmycins can serve as a potential agent for treating hypertrophic scar formation and other fibrotic disorders. Xiamenmycins are structurally, biosynthetically, and pharmacologically remarkable natural products for new anti-fibrotic drug discovery. The authors have a joint Chinese patent concerning xiamnemycin and its anti-fibrotic bioactivities.

Xiamycin, a Pentacyclic Indolosesquiterpene with Selective Anti-Hiv Activity from a Bacterial Mangrove Endophyte.

ChemInform Abstract: Xiamycin (I), a Pentacyclic Indolosesquiterpene with Selective Anti‐hiv Activity from a Bacterial Mangrove Endophyte.

Derivatives of Holomycin and Cyclopropaneacetic Acid from Streptomyces Sp Dt-A37

A Family of Multicyclic Indolosesquiterpenes from a Bacterial Endophyte

Medermycin-Type Naphthoquinones from the Marine-Derived Streptomyces Sp XMA39

Discovery of Three 22-Membered Macrolides by Deciphering the Streamlined Genome of Mangrove-Derived <i>Streptomyces</i> sp. HM190

Cyclic Depsipeptides and Linear Peptides with Cytotoxic and Antiphytopathogenic Activities from Symbiotic Bacteria Ofxenorhabdus(enterobacteriales: Morganellaceae) Genus

Bioactive Metabolites from Marine-Derived Streptomyces Sp A68 and Its Rifampicin Resistant Mutant Strain R-M1

Three New Isoflavonoid Glycosides From The Mangrove-Derived Actinomycete Micromonospora Aurantiaca 110b

New Polyene Macrolide Compounds from Mangrove-Derived Strain Streptomyces hiroshimensis GXIMD 06359: Isolation, Antifungal Activity, and Mechanism against Talaromyces marneffei

Angucycline antibiotics and its derivatives from marine-derived actinomycete Streptomyces sp. A6H

Identification Of Two Novel Anti-Fibrotic Benzopyran Compounds Produced By Engineered Strains Derived From Streptomyces Xiamenensis M1-94p That Originated From Deep-Sea Sediments

Indanomycin-related Antibiotics from Marine Streptomyces Antibioticus PTZ0016.

New Polyketides from the Marine-Derived Fungus Letendraea Sp. 5XNZ4-2

Hainanmycin A, a Cyclo-Heptadeca Macrolide Bearing a Cyclopentenone Moiety from the Mangrove-Derived Streptomyces Sp 219807

Deciphering the Streamlined Genome of Streptomyces Xiamenensis 318 As the Producer of the Anti-Fibrotic Drug Candidate Xiamenmycin

Halichoblelide D, A New Elaiophylin Derivative with Potent Cytotoxic Activity from Mangrove-Derived Streptomyces Sp 219807

A new xanthostatin analogue from the marine sponge-associated actinomycete Streptomyces sp. SCSIO 40064

Penicixanthene E, a new xanthene isolated from a mangrove-derived fungus Penicillium sp.

New Anti-Fibrotic Drug Candidates from Mangrove-Derived Streptomyces xiamenensis Suppressing Local Inflammation and Mechanical Stress in Hypertrophic Scars

Structural Diversity of Anti-Pancreatic Cancer Capsimycins Identified in Mangrove-Derived Streptomyces Xiamenensis 318 and Post-Modification Via a Novel Cytochrome P450 Monooxygenase